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Introduction
Acute graft-versus-host disease (GvHD) is a known 
complication of hematopoietic stem cell transplant 
previously thought to present primarily within the first 
100 days after stem cell transplant, although reports 
exist in the literature of acute GvHD presenting after 
this time period. Here we report a case of Stage IV 
TEN-like acute cutaneous GvHD occurring after 100 
days post-stem cell transplant in the setting of a 
recent decrease in immunosuppression. This case 
is of particular clinical interest given that to our 
knowledge, it is the first case describing a Stage IV 
acute GvHD skin reaction more than one year after 
allogeneic hematopoietic stem cell transplant.
Case Synopsis
A 50-year-old man with chronic lymphocytic leukemia 
(CLL) transformed to diffuse large B-cell lymphoma 
(DLBCL) two years previously was admitted for 
neutropenic septic shock. The dermatology team 
was consulted to evaluate a cutaneous eruption 
first noticed two weeks previously after the 
administration of quetiapine that persisted after 
quetiapine was switched to olanzapine. Over the past 
day, the primary team had noted new-onset multiple 
tender fluid-filled bullae over his bilateral forearms 
shortly after the initiation of amikacin, aztreonam, 
vancomycin, and metronidazole.
The patient’s oncologic history consisted of a 
diagnosis of CLL transformed to DLBCL approximately 
two years previously. He underwent several 
rounds of chemotherapy and ultimately received 
a matched unrelated donor stem cell transplant 20 
months prior to current presentation. He developed 
Stage I cutaneous GvHD that was managed by his 
Abstract
Acute graft-versus-host disease (GvHD) is a process 
that classically has been defined as occurring less 
than 100 days after stem cell transplant. When 
Stage IV cutaneous acute GvHD occurs outside this 
window, it can be difficult to distinguish clinically 
from toxic epidermal necrolysis (TEN). A 50-year-old 
man with diffuse large B-cell lymphoma who had 
undergone an allogeneic stem cell transplant 20 
months previously was admitted for neutropenic 
septic shock. He developed a slowly progressing 
macular/papular eruption with multiple tender 
bullae found to be consistent with TEN-like Stage IV 
cutaneous acute GvHD on biopsy. It was discovered 
that the patient’s maintenance immunosuppression 
had been completely discontinued one month 
prior to admission in preparation for clinical trial 
enrollment, causing a late presentation of cutaneous 
acute GvHD. This case provides particular insight into 
the diagnosis and management of late-presenting 
acute GvHD given that it is the first reported case of 
Stage IV cutaneous acute GvHD more than 12 months 
after stem cell transplant. In the setting of decreased 
immunosuppression in a patient with a history of a 
stem cell transplant, acute graft-versus-host disease 
must be considered regardless of the time that has 
elapsed since transplant.
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oncologist three months after transplant. He was 
then found to have recurrent DLBCL eight months 
prior to current presentation but had no response 
to further chemotherapy and was scheduled to be 
enrolled in the CAR-T (chimeric antigen receptor-T 
cell) trial. CAR-T therapy re-engineers patients’ own 
T cells to produce CD19-targeted chimeric antigen 
surface receptors that recognize and attack tumor 
cells. In preparation for enrollment, his maintenance 
immunosuppression (tacrolimus, rituximab, 
lenalidomide) was discontinued one month prior to 
current presentation.
Dermatologic examination revealed nearly confluent 
erythematous macules and papules overlying the 
bilateral arms and trunk with discrete, fully blanchable 
macules and papules over the bilateral legs. On the 
right upper arm, there was an erosion with denuded 
skin four centimeters in diameter. Three fluid-filled 
bullae two centimeters in diameter were noted on 
the left upper arm (Figure 1). The mucosal surfaces 
and palms and soles were clear.
A 4-mm lesional punch biopsy of a left upper arm 
lesion revealed a subepidermal necrotic bulla with 
lichenoid inflammation of the skin adnexa and 
extensive satellite cell necrosis noted to be consistent 
with toxic epidermal necrosis (TEN)-like acute graft-
versus-host disease. Stevens-Johnson syndrome and 
erythema multiforme were also in the differential 
diagnosis (Figure 2). A 4-mm perilesional punch 
biopsy sent for direct immunofluorescence showed 
no significant activity.
The patient was treated with 1 mg/kg of intravenous 
methylprednisolone for four days and with topical 
corticosteroids to affected skin twice daily. His 
methylprednisolone dose was then increased to 2 
mg/kg for an additional four days, completing a total 
of eight days of intravenous corticosteroids. He was 
then transitioned to oral prednisone 60 mg twice 
daily for two days and discharged on oral prednisone 
	
	
Figure 1. initial presentation of stage IV cutaneous acute graft-versus-host disease. From left to right: morbilliform eruption over chest; 
erosion with denuded skin on right arm; two fluid-filled bullae marked for biopsy.
Figure 2. Lichenoid process involving skin adnexa with extensive superficial epidermal necrosis suspicious for graft-versus-host 
disease from a 4-mm punch biopsy. From left to right: low power view revealing a necrotic epidermis with clefting and subepidermal 
bulla formation; higher power view revealing scattered inflammatory cells within the bulla and upper dermis with focal exocytosis of 
lymphocytes and dermal edema with mixed inflammatory infiltrate; and lichenoid adnexal inflammation with satellite cell necrosis. 
H&E, 4%, 10% and 20%, respectively.
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50 mg twice daily. Repeat dermatologic examination 
seven days later showed resolution of the eruption 
with no new bullae formation (Figure 3). Two weeks 
after discharge, the patient developed a severe 
infection and ultimately passed away.
Case Discussion
Acute graft-versus-host disease is a donor T cell 
mediated process in which donor T cells are activated 
against host antigens after allogeneic hematopoietic 
stem cell transplant. Activated effector T cells then 
migrate to the gut, liver, skin, lung, and lymphoid 
tissue and cause local tissue destruction [1]. Acute 
GvHD was classically thought to occur within 100 
days after stem cell transplant [2]. There is, however, a 
growing body of literature that discusses acute GvHD 
presenting after this time frame [3-5]. Holtan et al. 
defined this entity as late acute GvHD, performing 
the first prospective analysis of over 900 patients 
who developed symptoms of acute graft-versus-host 
disease greater than 100 days after hematopoietic cell 
transplant [6]. In cutaneous acute GvHD, skin lesions 
begin as erythematous macules and papules that 
coalesce into papules and plaques two to six weeks 
after transplant. The first lesion often begins around 
a hair follicle, with lesions appearing on the cheeks, 
neck, back, and palms and soles before spreading to 
the entire body. After initial presentation, the skin 
desquamates and may leave post-inflammatory 
changes [2].
Four clinical stages of cutaneous acute GvHD have 
been delineated. Stage I is defined as a macular/
papular rash involving 25 
percent of body surface 
area (BSA) or less. Stage 
II is defined as a macular/
papular rash involving 
25 to 50 percent BSA. 
Stage III is generalized 
erythroderma, whereas 
Stage IV is defined by toxic 
epidermal necrolysis-
like appearance with 
total dermatoepidermal 
separation visualized on 
dermatopathology [2]. 
Current studies of patients 
with cutaneous acute GvHD 
have shown that approximately 2% of cases will be 
classified as Stage IV disease [7].
Per this staging system, our patient had Stage IV acute 
GvHD. Although his disease manifested after 100 
days post-transplant, he had acute disease clinically 
and histologically. Our patient’s maintenance 
tacrolimus, rituximab, and lenalidomide had been 
discontinued one month prior to his presentation in 
preparation for enrollment in the CAR-T trial. Given 
that the patient had already had a mild episode of 
cutaneous graft-versus-host disease three months 
after his stem cell transplant, the recent decrease 
in immunosuppression likely triggered a flare of 
acute GvHD despite the unusual time course. This 
phenomenon of GvHD of this severity erupting 
immediately after a reduction in immunosuppression 
has not been described in the existing literature to 
our knowledge. In 2001, Valks et al. described a series 
of three patients in whom clinical and pathological 
features of acute GvHD developed greater than 100 
days after peripheral blood stem cell transplant or 
allogeneic bone marrow transplant. All patients had 
a flare of grade II acute GvHD that occurred after 
tapering their prophylactic regimens of cyclosporine 
in combination with either methotrexate or 
corticosteroids [3]. Later that year, Wollina et al. 
described a case of a 40-year-old woman who had a 
peripheral blood stem cell transplant in September 
1998 who presented nine months later with stage I 
acute graft-versus-host disease within one week of 
her prophylactic prednisone dose being tapered [4]. 
Our case is unique from those which were previously 
	
	
Figure 3. resolution of stage IV cutaneous acute graft-versus-host disease. From left to right: 
patient’s left arm with dry exfoliative scale and resolution of previous erythema and bullae; 
abdomen clear of lesions.
Volume 23 Number 10 | October 2017 
DOJ 23 (10): 7
- 4 - 
Dermatology Online Journal  ||  Case Presentation
published and of particular clinical interest given 
the severity, rapid onset, and extensive nature of our 
patient’s GvHD.
First-line therapy for the treatment of grades II to IV 
acute GvHD is IV methylprednisone started at a dose 
of 2 milligrams/kilogram/day [8]. A meta-analysis 
looking at augmentation of 2 mg/kg prednisone 
with higher doses of corticosteroids, infliximab, 
antithymocyte globulin, mycophenolate mofetil, 
CD5-specific immunotoxin, and anti-IL2 receptor Ab 
found no increased efficacy with the addition of a 
second immunosuppressant [9]. High potency topical 
corticosteroids can be used in isolation for patients 
with stage I cutaneous acute GvHD with no evidence 
of systemic involvement [10]. Lastly, phototherapy 
has been shown to be useful for clearing cutaneous 
GvHD, but further data is needed to fully characterize 
its use [11].
Our patient initially responded well to therapy, 
but Stage IV cutaneous acute GvHD portends an 
extremely poor prognosis in the literature. In one 
study detailing fifteen cases of Stage IV cutaneous 
acute GvHD, thirteen patients (87%) died within 12 
months, with the median time of death from onset 
of disease being 33 days. Causes of death included 
pulmonary GvHD, CMV infection, sepsis, pneumonia, 
GI bleed, hepatic failure, hemorrhage, GvHD 
involving the CNS, acute leukemia, and endocarditis. 
Of these thirteen patients, five of them had cleared 
their cutaneous acute GvHD at time of death with 
corticosteroids and other immunosuppressants. 
The two patients alive at the end of the study had 
also recovered from their cutaneous disease [12]. 
Similarly, our patient had cleared his cutaneous 
GvHD at the time of his death and ultimately died 
from an infection.
Minimal literature exists characterizing the difference 
in outcomes between patients presenting with early- 
versus late-onset acute GvHD of all types. In one study 
among patients with late-onset acute GvHD, defined 
as acute GvHD presenting greater than 100 days after 
transplant, 52% had acute GvHD that persisted, 39% 
had recurrent disease, and 9% had de novo disease. 
At two years, more patients with late acute GvHD had 
progressed to chronic GvHD compared to early acute 
GvHD (48% versus 31%). Overall survival, however, 
was higher in late acute GvHD when compared to 
early acute GvHD (59% versus 50%). Lastly, unrelated 
donor transplantations were associated with a higher 
risk of mortality in patients with late acute GvHD as 
compared to early acute GvHD, with the hazard ratio 
being 6.1 [13].
Conclusion
Ultimately, in the setting of decreased 
immunosuppression in a patient who has had a stem 
cell transplant at any time point, acute graft-versus-
host disease must be considered in the differential 
diagnosis.
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